Market closedNon-fractional
ADC Therapeutics/ADCT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ADC Therapeutics
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
Ticker
ADCT
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology
Headquarters
Epalinges, Switzerland
Employees
274
Website
www.adctherapeutics.com
ADC Therapeutics Metrics
BasicAdvanced
$368M
Market cap
-
P/E ratio
-$2.77
EPS
1.62
Beta
-
Dividend rate
Price and volume
Market cap
$368M
Beta
1.62
Financial strength
Current ratio
4.608
Quick ratio
4.088
Long term debt to equity
-222.632
Total debt to equity
-223.369
Interest coverage (TTM)
-3.08%
Management effectiveness
Return on assets (TTM)
-24.08%
Return on equity (TTM)
289.97%
Valuation
Price to revenue (TTM)
4.573
Price to book
-1.63
Price to tangible book (TTM)
-1.63
Price to free cash flow (TTM)
-2.09
Growth
Revenue change (TTM)
-62.38%
Earnings per share change (TTM)
9.58%
3-year earnings per share growth (CAGR)
-7.88%
What the Analysts think about ADC Therapeutics
Analyst Ratings
Majority rating from 7 analysts.
ADC Therapeutics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$18M
-74.10%
Net income
-$47M
-80.58%
Profit margin
-258.88%
-25.03%
ADC Therapeutics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.58
-$0.58
-$1.03
-$0.56
-
Expected
-$0.46
-$0.63
-$0.50
-$0.56
-$0.44
Surprise
26.87%
-8.55%
104.77%
0.78%
-
ADC Therapeutics News
AllArticlesVideos
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
GlobeNewsWire·3 weeks ago
ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewsWire·3 months ago
ADC Therapeutics SA (ADCT) Q1 2024 Earnings Call Transcript
Seeking Alpha·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADC Therapeutics stock?
ADC Therapeutics (ADCT) has a market cap of $368M as of July 27, 2024.
What is the P/E ratio for ADC Therapeutics stock?
The price to earnings (P/E) ratio for ADC Therapeutics (ADCT) stock is 0 as of July 27, 2024.
Does ADC Therapeutics stock pay dividends?
No, ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ADC Therapeutics dividend payment date?
ADC Therapeutics (ADCT) stock does not pay dividends to its shareholders.
What is the beta indicator for ADC Therapeutics?
ADC Therapeutics (ADCT) has a beta rating of 1.62. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell ADC Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.